FAIR LAWN, N.J.--(BUSINESS WIRE)--Aug. 10, 2006--Vyteris Holdings (Nevada), Inc. (OTC BB:VYHN) today reported that data from two Phase I clinical trials demonstrated that Vyteris’ Actyve(TM) transdermal drug delivery technology delivered potentially therapeutic levels of a peptide, that is used for the treatment of infertility, in humans. Vyteris and its partner, Ferring Pharmaceuticals Inc., are in the early stages of developing a product that delivers the peptide for the treatment of female infertility. The development goal is that, through this technology, the peptide could be delivered 24 hours a day in short pulses, to induce ovulation.
